The Breast Cancer Index (BCI) is a gene expression-based biomarker developed using a cohort of ER+ lymph node-negative patients from the randomized prospective Stockholm trial using two biomarkers, the HOXB13:IL17BR ratio (H/I) and the molecular grade index (MGI) [32]. Here, ESR1 is linked to breast carcinoma.